Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Biology of Waldenström macroglobulinemia

Véronique Leblond • 1 Sep 2020
EBMT 2020
Rare Diseases Waldenström’s Macroglobulinemia Antibodies Bendamustine Ibrutinib Rituximab

Véronique Leblond, MD, Hematology at Pitié Salpêtrière Hospital, Paris, France, discusses common genetic variations seen in patients with Waldenström macroglobulinemia and touches on how a greater understanding of the disease, can support treatment strategies, including treatment with ibrutinib, a tyrosine kinase inhibitor. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Véronique Leblond

CLL: the GREEN study
3:06
CLL: the GREEN study
Véronique Leblond • 20 Aug 2020
Current research in Waldenström’s macroglobulinemia
1:43
Current research in Waldenström’s macroglobulinemia
Véronique Leblond • 20 Aug 2020
Overview of the clinical trial of ibrutinib vs chlorambucil as front-line therapy
1:14
Overview of the clinical trial of ibrutinib vs chlorambucil as front-line therapy
Véronique Leblond • 4 Dec 2015
Obinutuzumab (GA101) plus bendamustine as front-line therapy in CLL
3:22
Obinutuzumab (GA101) plus bendamustine as front-line therapy in CLL
Véronique Leblond • 4 Dec 2015

Related Videos

BPDCN: unmet needs, CD123-targeted therapies and novel targets
15:50
BPDCN: unmet needs, CD123-targeted therapies and novel targets
Naveen Pemmaraju • 19 Sep 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
1:39
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
Elena Zamagni • 25 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals